[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100282275":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":23,"locations":28,"responsibleParty":45,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IgA nephropathy group",null,"Eligible biopsy-proven primary IgA nephropathy patients.",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No intervention",[9],[19],{"name":20,"affiliation":21,"role":22},"Xue Qing Yu, M.D. & Ph.D.","First Affiliated Hospital, Sun Yat-Sen University","PRINCIPAL_INVESTIGATOR",[24],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","8620-87766335","yuxq@mail.sysu.edu.cn",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"The First Affiliated Hospital,Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510080","China",{"type":37,"coordinates":38},"Point",[39,40],113.25,23.11667,{"lat":40,"lon":39},[43],{"name":44,"role":25,"phone":26,"phoneExt":10,"email":27},"Xue Qing Yu, M.D.& Ph.D.",{"type":22,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Xue Qing Yu","Professor","100282275",false,"NCT02954419","IgA Nephropathy Biomarkers Evaluation Study (INTEREST)","INTEREST","Inclusion Criteria:\n\n* Male or female individuals aged 14 years or older\n* Patients with biopsy-proven primary IgA nephropathy\n* A renal biopsy available for reviewing must include 10 or more glomeruli.\n* The first renal biopsy was performed within 3 years.\n* eGFR ≥ 60 ml\u002Fmin\u002F1.73 m2 (MDRD formula);\n* Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n* Relatives were diagnosed with biopsy-proven primary IgA nephropathy;\n* Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.","ALL","14 Years",{"count":57,"type":58},2000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml\u002Fmin\u002F1.73 m2).",[62,63],"IgA Nephropathy","Glomerular Diseases",[62,65],"Biomarker","2026-04-08",{"date":68,"type":69},"2026-04-13","ACTUAL",{"date":71,"type":10},"2016-11",{"date":73,"type":58},"2027-01",{"name":5,"class":6},1]